0.93%
-13.41%
-11.94%
-29.88%
-4.41%
-25.46%
17.14%
AI Spotlight on BIOT
Company Description
Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications.The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems and flash system accessories; normal, reversed, and speciality phase cartridges; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts.It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and government authorities and academic institutions, as well as clinical, forensic, and academic laboratories.It operates in 70 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific.Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.
Market Data
| Last Price | 140.8 |
| Change Percentage | 0.93% |
| Open | 140 |
| Previous Close | 139.5 |
| Market Cap ( Millions) | 11178 |
| Volume | 29006 |
| Year High | 202.2 |
| Year Low | 130.3 |
| M A 50 | 153.35 |
| M A 200 | 170.98 |
Financial Ratios
| FCF Yield | 2.16% |
| Dividend Yield | 1.14% |
| ROE | 6.79% |
| Debt / Equity | 6.56% |
| Net Debt / EBIDTA | -21.35% |
| Price To Book | 2.96 |
| Price Earnings Ratio | 43.86 |
| Price To FCF | 46.19 |
| Price To sales | 5.28 |
| EV / EBITDA | 19.68 |
News
- 05:03 - 3 Undiscovered Gems with Promising Potential
- Dec -25 - Exploring Three Undiscovered Gems with Strong Potential
- Nov -22 - Uncover These 3 Undiscovered Gems with Promising Potential
- Oct -24 - Biotage AB (BITGF) Q3 2024 Earnings Call Highlights: Strong Organic Growth Amidst Market Challenges
- Oct -21 - 3 Swedish Stocks Estimated To Be Trading Below Intrinsic Value In October 2024
- Oct -03 - Three Swedish Stocks Estimated To Be Trading Below Intrinsic Value
- Sep -18 - Biotage And 2 More Value Stock Picks On The Swedish Exchange
- Sep -02 - Spotlighting Sweden's Undiscovered Gems This September 2024
- Aug -21 - Discovering 3 Undiscovered Gems in Sweden with Strong Potential
- Aug -19 - Undiscovered Gems In Sweden To Watch This August 2024
- Aug -02 - Unveiling 3 Undiscovered Gems In Sweden With Strong Potential
- Aug -01 - Exploring 3 Undiscovered Swedish Gems with Strong Fundamentals
- Jul -31 - Swedish Undiscovered Gems Backed By Strong Fundamentals
- Jul -30 - Exploring Betsson And Two Other Hidden Swedish Stock Gems
- Jul -29 - Exploring Undiscovered Swedish Stocks July 2024
- Jul -24 - Exploring Biotage And Two Other Promising Small Caps In Sweden
- Jul -23 - Exploring Undervalued Small Caps With Insider Actions In July 2024
- Jul -23 - Exploring Biotage And Two More Undiscovered Swedish Gems
- Jul -22 - Exploring Three Undervalued Small Caps With Insider Action In The Region
- Jul -19 - KKR Said to Mull Options for Stake in Life Sciences Firm Biotage
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Small Molecules & Synthetic Therapeutics
Expected Growth : 10 %
What the company do ?
Small Molecules & Synthetic Therapeutics from Biotage AB (publ) develops and manufactures chemical compounds for pharmaceutical and biotech industries.
Why we expect these perspectives ?
Biotage AB's Small Molecules & Synthetic Therapeutics segment is driven by increasing demand for efficient drug discovery and development, growing adoption of personalized medicine, and rising investments in R&D by pharmaceutical companies. Additionally, advancements in synthetic chemistry and process optimization are fueling growth, with a 10% growth rate expected.
Segment n°2 -> Biologics & Advanced Therapeutics
Expected Growth : 12 %
What the company do ?
Biologics & Advanced Therapeutics from Biotage AB (publ) develops and manufactures biopharmaceuticals, including antibodies, proteins, and vaccines, using advanced technologies.
Why we expect these perspectives ?
Strong demand for biologics and advanced therapeutics drives 12% growth. Increasing adoption of precision medicine, rising prevalence of chronic diseases, and growing investment in R&D for novel therapies contribute to this growth. Additionally, Biotage AB's (publ) expertise in purification and analytical technologies supports the development of complex biologics, further fueling growth in this segment.
Segment n°3 -> Analytical Testing
Expected Growth : 9 %
What the company do ?
Analytical Testing from Biotage AB (publ) involves evaluating the chemical composition and structure of substances using various analytical techniques, such as chromatography and spectroscopy, to identify and quantify components.
Why we expect these perspectives ?
Biotage AB's 9% growth in Analytical Testing is driven by increasing demand for pharmaceutical and biotechnology research, expansion into emerging markets, and strategic partnerships. Additionally, the company's innovative product portfolio, including its flagship evaporation systems, and investments in R&D have contributed to its growth momentum.
Segment n°4 -> Scale-up
Expected Growth : 11 %
What the company do ?
Scale-up from Biotage AB (publ) refers to the expansion of its operations, increasing production capacity to meet growing demand for its purification systems and separations equipment.
Why we expect these perspectives ?
Biotage AB's 11% scale-up growth is driven by increasing demand for purification solutions in the pharmaceutical and biotechnology industries, expansion into emerging markets, strategic partnerships, and continuous innovation in product offerings, such as the launch of new flash cartridges and automated purification systems.
Segment n°5 -> Water & Environmental Testing
Expected Growth : 8 %
What the company do ?
Water & Environmental Testing from Biotage AB (publ) provides analytical solutions for detecting contaminants and pollutants in water, air, and soil, ensuring environmental sustainability.
Why we expect these perspectives ?
Biotage AB's 8% growth in Water & Environmental Testing is driven by increasing regulations and standards for water quality, rising demand for environmental monitoring, and growing adoption of analytical instruments in emerging markets. Additionally, the company's innovative products and services, such as its automated sample preparation systems, are gaining traction with customers.
Segment n°6 -> Diagnostics
Expected Growth : 13 %
What the company do ?
Diagnostics from Biotage AB (publ) refers to the development and manufacturing of products for bioanalytical and bioprocessing applications, enabling researchers and manufacturers to improve efficiency and quality in their workflows.
Why we expect these perspectives ?
Biotage AB's 13% growth is driven by increasing demand for diagnostic solutions, expansion into emerging markets, and strategic partnerships. The company's innovative product portfolio, including its flagship sample preparation and purification systems, has enabled it to capitalize on the growing need for efficient and accurate diagnostic testing.
Biotage Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| Biotage Selekt | A flash purification system designed for rapid and efficient purification of synthetic compounds |
| Biotage Isolera | A flash chromatography system for purification of compounds in pharmaceutical, biotech, and academic research |
| Biotage Horizon | A software platform for analytical and purification systems, providing data management and workflow optimization |
| Biotage Pyrosequencing | A sequencing technology for genetic analysis, providing high-resolution genotyping and methylation analysis |
| Biotage Sample Prep | A range of sample preparation products for DNA, RNA, and protein extraction, purification, and analysis |
| Biotage Peptide Synthesis | A range of products for peptide synthesis, including resins, linkers, and reagents |
Biotage AB (publ)'s Porter Forces
Threat Of Substitutes
Biotage AB (publ) operates in a niche market with limited substitutes, but there are some alternatives available, which reduces the threat of substitutes.
Bargaining Power Of Customers
Biotage AB (publ) has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Biotage AB (publ) relies on a few key suppliers for critical components, which gives them some bargaining power. However, the company's strong relationships with suppliers and its ability to negotiate prices mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to compete with established players like Biotage AB (publ).
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players competing for market share. Biotage AB (publ) faces intense competition from companies with similar products and technologies, which increases the intensity of rivalry.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 13.09% |
| Debt Cost | 3.95% |
| Equity Weight | 86.91% |
| Equity Cost | 8.01% |
| WACC | 7.48% |
| Leverage | 15.07% |
Biotage AB (publ) : Quality Control
Biotage AB (publ) passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| TDVOX.ST | Tobii Dynavox AB (Publ) develops and sells assistive technology products for communication in Sweden and internationally. The company provides technology and solutions for augmentative and alternative communication for people with … |
| TSTL.L | Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and … |
| VBSN.SW | IVF Hartmann Holding AG provides medical consumer goods in Switzerland and internationally. The company offers surgical disposable instruments, blankets, clothing and gloves, disinfection and hygiene products, wound management and hydrotherapy … |
| SKAN.SW | SKAN Group AG provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Asia, Europe, the Americas, and internationally. It operates in two segments: Equipment and Solutions … |
| CLTN.SW | COLTENE Holding AG develops, manufactures, and sells disposables, tools, and equipment for dentists and dental laboratories in Europe, the Middle East, Africa, North America, Latin America, and Asia/Oceania. It offers … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
IVF Hartmann Holding
A-Score
1-Year Total Return ->
🥈
SKAN
A-Score
1-Year Total Return ->
🥉
Biotage
A-Score
1-Year Total Return ->
4
Tristel
A-Score
1-Year Total Return ->
5
Coltene
A-Score
1-Year Total Return ->
6
